Genentech Finds Another Nanoparticle Partner In COUR

Follows January Collaboration With GenEdit

 
• By Mandy Jackson
  
COUR uses its tolerogenic nanoparticle technology to develop treatments that provide antigen-specific tolerance in immune-mediated diseases (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Scrip